EICHOR
● Active Not Recruiting
A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension
Condition: Hypertension, Pulmonary · Sponsor: Actelion
About this study
The purpose of this study is to evaluate whether the addition of selexipag to standard of care treatment delays disease progression in children with Pulmonary Arterial Hypertension (PAH) in comparison to placebo.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (116)
| Phoenix Children's Hospital | Phoenix, Arizona, United States | — |
| UCLA Medical Center | Los Angeles, California, United States | — |
| UCSF | San Francisco, California, United States | — |
| Childrens Hospital Colorado | Aurora, Colorado, United States | — |
| Children's National Medical Center | Washington D.C., District of Columbia, United States | — |
| Congenital Heart Center of the University of Florida | Gainesville, Florida, United States | — |
| Riley Hospital for Children | Indianapolis, Indiana, United States | — |
| Detroit Medical Center | Detroit, Michigan, United States | — |
| Cincinnati Children's Hospital Medical Center | Cincinnati, Ohio, United States | — |
| Childrens Hospital Of Philadelphia | Philadelphia, Pennsylvania, United States | — |
| Texas Children's Hospital | Houston, Texas, United States | — |
| Primary Children's Hospital | Salt Lake City, Utah, United States | — |
+ 104 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.